Brevan Howard Capital Management 13F: Cuts BBIO Stake by $6.8M

Brevan Howard Capital Management Trims Position in BridgeBio Pharma

Brevan Howard Capital Management cut its holdings in BridgeBio Pharma, Inc. (NasdaqGS: BBIO) during the period ended May 15, 2026, according to a recent Form 13F filing with the SEC. The fund sold 91,953 shares, reducing its investment by 52.9%. Institutional filings reflect holdings as of the reporting date and may not represent current positions.

How Brevan Howard Adjusted Its BridgeBio Pharma Shares

The fund previously held 173,523 shares of the biotechnology company. Following the sale of 91,953 shares, Brevan Howard finished the period with 81,570 shares. The remaining stake carried a reported market value of approximately $6.07 million based on the filing details.

BridgeBio Pharma Stock Trades Near 200-Day Average

BridgeBio Pharma shares trade near $74.48. The stock has moved between a 52-week low of $48.78 and a 52-week high of $93.42. Its 50-day moving average sits at $79.14, while its 200-day moving average is $73.91. The company carries a market capitalization of $13.01 billion and a forward P/E of 2,423.735.

Recent Insider Transactions at BridgeBio Pharma

Insiders have been active in company shares alongside institutional shifts. On June 22, 2026, Hannah Valantine disposed of 2,808 shares at a zero-dollar transaction price recorded in filings. On the same day, June 22, 2026, Douglas Dachille acquired 3,990 shares, also noted at a zero-dollar price per share in disclosures.

Analysts Set New Price Targets

Wall Street firms maintain positive views on the stock. On October 7, 2026, Barclays maintained its Overweight rating and lowered its price target to $156.0 from $157.0. On September 10, 2026, HC Wainwright & Co. reiterated a Buy rating with a $120.0 target. Earlier, on September 1, 2026, Mizuho maintained an Outperform rating while lifting its target to $110.0 from $96.0. Truist Securities maintained a Buy rating on August 12, 2026, with a $107.0 target. Canaccord Genuity maintained a Buy rating on August 12, 2026, at a $106.0 target. JP Morgan maintained an Overweight rating on August 12, 2026, moving its target to $111.0 from $100.0. B of A Securities maintained a Buy rating on August 11, 2026, with a $104.0 target. The stock holds a consensus strong buy rating from 21 analysts, with a target mean price of $109.10.

About BridgeBio Pharma

BridgeBio Pharma, Inc. is a Palo Alto-based biopharmaceutical company founded in 2015 that discovers, develops, and delivers medicines for patients with genetic diseases and cancers. Its portfolio includes treatments for transthyretin amyloidosis, molybdenum cofactor deficiency, and achondroplasia. The company employs 999 people and relies on collaborations with academic institutions and major drug makers to advance its clinical pipeline.

What to Watch Next for BridgeBio Pharma

Investors will look toward the company's next earnings report, scheduled for October 28, 2026, for updates on its clinical programs and financial progress. Institutional ownership updates will arrive in subsequent SEC filings, while ongoing insider reports will track executive transactions without serving as trading signals.